Parabilis Medicines, Inc. - Common Stock (NQ:PBLS)

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 01, 2026

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Performance

52-Week Range 40.7% below 52-week high

25.18

24.5152W Low 42.4852W High

1 Week 14.6% below 1-week high

24.801W Low 29.501W High

Parabilis Medicines, Inc. - Common Stock (PBLS) traded between $24.51 and $42.48 over the past 52 weeks and last traded at $25.18, 40.7% below its 52-week high. Over the past week it ranged between $24.80 and $29.50.

Past 12 Months

-8.4%

-29.5%

-13.4%

-20.3%

1W -$2.30

1M -$10.54

3M -$3.88

6M -$6.42

YTD -$6.42

1Y -$6.42

PBLS was -20.3% over the past year, -20.3% over six months, -20.3% year to date, -8.4% in the last week.

12 Months vs Market

PBLS

-20.3%

DIA

+12.6%

SPY

+16.0%

QQQ

+20.9%

IWM

+9.9%

Over the past 12 months PBLS returned -20.3% versus DIA (Dow) +12.6%, SPY (S&P 500) +16.0%, QQQ (Nasdaq 100) +20.9% and IWM (Russell 2000) +9.9%.

Volume & Liquidity

1.0M

1.3M

724.4K

810.5K

YTD

810.5K

PBLS's 3-month average daily volume is 724.4K.

More News

August 13, 2026

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗

June 27, 2026

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors

August 25, 2026

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy? ↗

June 20, 2026

SpaceX Climbed Nearly 20% in Its First Day of Trading. Here's Where the Stock Price Will Be in 3 Months, According to History. ↗

June 15, 2026

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? ↗

June 12, 2026

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 11, 2026